OCAT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCAT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ocata Therapeutics's gross profit for the three months ended in Sep. 2015 was $0.07 Mil. Ocata Therapeutics's gross profit for the trailing twelve months (TTM) ended in Sep. 2015 was $0.14 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Ocata Therapeutics's gross profit for the three months ended in Sep. 2015 was $0.07 Mil. Ocata Therapeutics's Revenue for the three months ended in Sep. 2015 was $0.08 Mil. Therefore, Ocata Therapeutics's Gross Margin % for the quarter that ended in Sep. 2015 was 82.14%.
Ocata Therapeutics had a gross margin of 82.14% for the quarter that ended in Sep. 2015 => Durable competitive advantage
The historical data trend for Ocata Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocata Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | |||||||||||
Gross Profit | Get a 7-Day Free Trial | 0.51 | 0.16 | 0.35 | 0.14 | 0.10 |
Ocata Therapeutics Quarterly Data | ||||||||||||||||||||
Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | |
Gross Profit | Get a 7-Day Free Trial | 0.02 | 0.02 | 0.02 | 0.02 | 0.07 |
For the Biotechnology subindustry, Ocata Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ocata Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Ocata Therapeutics's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Ocata Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2014 is calculated as
Gross Profit (A: Dec. 2014 ) | = | Revenue | - | Cost of Goods Sold |
= | 0.158 | - | 0.063 | |
= | 0.10 |
Ocata Therapeutics's Gross Profit for the quarter that ended in Sep. 2015 is calculated as
Gross Profit (Q: Sep. 2015 ) | = | Revenue | - | Cost of Goods Sold |
= | 0.084 | - | 0.015 | |
= | 0.07 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Ocata Therapeutics's Gross Margin % for the quarter that ended in Sep. 2015 is calculated as
Gross Margin % (Q: Sep. 2015 ) | = | Gross Profit (Q: Sep. 2015 ) | / | Revenue (Q: Sep. 2015 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.07 | / | 0.084 | |
= | 82.14 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ocata Therapeutics (NAS:OCAT) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ocata Therapeutics had a gross margin of 82.14% for the quarter that ended in Sep. 2015 => Durable competitive advantage
Thank you for viewing the detailed overview of Ocata Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Levy | director | |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Edward H Myles | officer: COO & CFO | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Paul K Wotton | director, officer: President and CEO | C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341 |
Jooste H Le Roux | officer: SVP of Bus Development & CCO | C/O NABI BIOPHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487 |
Gregory D Perry | director | C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451 |
Robert Langer | director | 98 MONTVALE RD, NEWTON MA 02459 |
Michael D West | director | AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501 |
Pedro Huertas | officer: Chief Development Officer | 950 WINTER STREET, NORTH, WALTHAM MA 02451 |
Alan G Walton | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 385 E. COLORADO BLVD., SUITE 299, PASADENA CA 91101 |
Robert Peabody | director, officer: VP - Grant Administration | ONE INNOVATION DRIVE, WORCHESTER MA 01605 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.